Daniel J Benedetti, Lindsay A Renfro, Ian Tfirn, Najat C Daw, John A Kalapurakal, Peter F Ehrlich, Geetika Khanna, Elizabeth Perlman, Anne Warwick, Kenneth W Gow, Arnold C Paulino, Nita L Seibel, Paul Grundy, Conrad V Fernandez, James I Geller, Elizabeth A Mullen, Jeffrey S Dome
BACKGROUND: On the fifth National Wilms Tumor Study, treatment for clear cell sarcoma of the kidney (CCSK) included combined vincristine, doxorubicin, cyclophosphamide, and etoposide (regimen I) plus radiation therapy (RT), yielding 5-year event-free survival (EFS) rates of 100%, 88%, 73%, and 29% for patients who had with stage I, II, III, and IV disease, respectively. In the Children's Oncology Group study AREN0321 of risk-adapted therapy, RT was omitted for stage I disease if lymph nodes were sampled, and carboplatin was added for stage IV disease (regimen UH-1)...
February 23, 2024: Cancer